Our biomarker-driven approach will
redefine cancer treatment.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
-
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
-
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
-
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Investors
- Clinical Trials
- Programs
- Therapeutic Areas
